The evaluation of CYP2D6, CYP2C9 and CYP2C19 polymorphisms by genosensor for personalized medicine in psychiatry patients

The cytochrome P450 proteins are drug-metabolizing enzymes that involves in many catalytic reactions. Genetic variability (polymorphism) in these enzymes may influence a patient’s response to commonly prescribed drug classes, including beta blockers and antidepressants. The aim of this study is to evaluate the CYP2D6, CYP2C9, CYP2C19 polymorphisms of shizophrenic and bipolar patients in the therapeutic response that allow the treatment to be individualized. This study was carried out on patients who attended the Cukurova University Psychiatric Unit with a diagnosis of schizophrenia and bipolar disorder involved in our study. There are several drugs should dose adjustment, reduce the toxicity and increase the effects for P450 enzymes. Genetic polymorphism of human enzymes and receptors known in the treatment process, may be important to maintain the availability of the treatment. This information may allow the prediction of therapeutic response or treatment to be individualized.